Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03477019 | Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer | completed | Phase 1 / Phase 2 | 17 | St. Olavs HospitalOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT00773695 | A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer | completed | Phase 2 | 150 | Hoffmann-La RocheINDUSTRY | 1 | Jan 9, 2023 |
| clinicaltrials |
| NCT02438358 | Feasibility Study of Intraoperative Imaging in Breast Cancer | completed | Phase 1 / Phase 2 | 60 | Lumicell, Inc.INDUSTRY | 1 | Jan 5, 2023 | clinicaltrials |
| NCT02440230 | Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients(SEAT) | completed | Phase 2 | 110 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 30, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT02229136 | Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus | completed | Phase 2 | 104 | US Oncology ResearchINDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer(TOPACIO) | completed | Phase 1 / Phase 2 | 122 | Tesaro, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03735966 | Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients. | completed | Phase 2 | 75 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 1, 2022 | clinicaltrials |
| NCT01752907 | Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim(VINE) | completed | Phase 2 | 304 | AmgenINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT03344536 | A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05206656 | Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer | completed | Phase 2 | 80 | Hunan Cancer HospitalOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT00270413 | SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer | completed | Phase 2 | 19 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT00691678 | Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer | completed | Phase 2 | 53 | Dawn L. HershmanOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04871854 | Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints | completed | Phase 2 | 100 | Beni-Suef UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02489448 | Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 68 | Yale UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT04676516 | A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer(OTT-19-06) | completed | Phase 2 | 40 | Ottawa Hospital Research InstituteOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT02448771 | A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer | completed | Phase 1 / Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02910219 | Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients(HALT-D) | completed | Phase 2 | 53 | Sandra SwainOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT00530868 | Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer | completed | Phase 2 | 75 | University of Alabama at BirminghamOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT00930579 | Pre-Surgical Study: Effect of Metformin on Breast Cancer Proliferation | completed | Phase 2 | 35 | Columbia UniversityOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02730130 | Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients | completed | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT02285179 | Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen(Poseidon) | completed | Phase 1 / Phase 2 | 189 | The Netherlands Cancer InstituteOTHER | 4 | Oct 12, 2022 | clinicaltrials |
| NCT02806050 | Palbociclib and FES PET | completed | Phase 2 | 30 | University Medical Center GroningenOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03057600 | Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) | completed | Phase 2 | 52 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02370238 | A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer(FRIDA) | completed | Phase 2 | 194 | Dompé Farmaceutici S.p.AINDUSTRY | 7 | Sep 16, 2022 | clinicaltrials |
| NCT03167619 | Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)(DORA) | completed | Phase 2 | 45 | Duke UniversityOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03154749 | DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer | completed | Phase 2 | 93 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT03394027 | ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT01791985 | AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)(RADICAL) | completed | Phase 1 / Phase 2 | 52 | Imperial College LondonOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02506556 | Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer(PIKNIC) | completed | Phase 2 | 38 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT04075604 | A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer(CheckMate 7A8) | completed | Phase 2 | 23 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 10, 2022 | clinicaltrials |
| NCT01989780 | Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer(BOOSTER) | completed | Phase 2 | 160 | Japan Breast Cancer Research GroupOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT00468715 | Bicalutamide in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02657343 | An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. | completed | Phase 1 / Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT02177175 | Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification | completed | Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT02282345 | Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer | completed | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT00828854 | Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing | completed | Phase 2 | 27 | Syndax PharmaceuticalsINDUSTRY | 2 | Jun 30, 2022 | clinicaltrials |
| NCT01990209 | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) | completed | Phase 2 | 71 | SCRI Development Innovations, LLCOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT01082211 | Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery | completed | Phase 2 | 65 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT03184090 | Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC(BioPER) | completed | Phase 2 | 33 | MedSIROTHER | 2 | Jun 21, 2022 | clinicaltrials |
| NCT03291886 | Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer | completed | Phase 2 | 133 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02379247 | BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer | completed | Phase 1 / Phase 2 | 43 | Priyanka SharmaOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT03948477 | Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy(PantoCIN) | completed | Phase 2 | 160 | University of Auckland, New ZealandOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT02789657 | Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. | completed | Phase 2 | 32 | Brown UniversityOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT02536794 | MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT00676663 | Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer(ENCORE301) | completed | Phase 2 | 130 | Syndax PharmaceuticalsINDUSTRY | 5 | May 11, 2022 | clinicaltrials |
| NCT01904903 | Cardiac Safety Study in Patients With HER2 + Breast Cancer(SAFE-HEaRt) | completed | Phase 2 | 31 | Medstar Health Research InstituteOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT02400476 | An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide | completed | Phase 2 | 563 | Puma Biotechnology, Inc.INDUSTRY | 7 | May 6, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Jan 19, 2023source: clinicaltrials